BDX Stock Forecast & Price Target

Becton Dickinson's positioning in the Biosurgery market, which is valued at nearly $400 million and growing at approximately 5%, enhances its revenue potential. The company's continued commitment to the Chinese market, with volume-based procurement expected to encompass around 80% of the portfolio by the end of 2026, signals strong volume growth prospects in that region. Additionally, BD Connected Care demonstrated notable performance with sales reaching $1.13 billion, reflecting a 4.7% year-over-year increase, further indicating robust overall growth across multiple segments.

The outlook for Becton Dickinson's stock remains negative due to several fundamental issues, including a commitment to reducing leverage from approximately 3x to 2.5x, which may take 12-18 months and reflects ongoing financial pressure. Additionally, the company is facing persistent revenue decline in certain segments, such as Alaris, and continues to experience challenging market dynamics, particularly in China, and lower funding in lifesciences research that negatively impacts overall performance. Lastly, the anticipated margin headwinds from various business investments, tariffs, and dilution from mergers and acquisitions, along with an expected drag on growth from remediation efforts, further complicate Becton Dickinson's path to achieving meaningful earnings per share growth in the near future.